By CBJ News Staff [email protected] KemPharm, Inc. announced today the U.S. Food and Drug Administration had accepted the New Drug Application for its investigational attention deficit hyperactivity disorder (ADHD) treatment, KP415. The Florida-based specialty pharmaceutical company, with locations in Coralville…